Clinical trial
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
NCT00469469 · Dartmouth-Hitchcock Medical Center, Other · Withdrawn
Key facts
| NCT number | NCT00469469 |
|---|---|
| Title | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma |
| Official title | A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adrenocortical Carcinoma |
| Intervention type | Drug |
| Interventions | Bevacizumab |
| Enrollment | 0 |
| Start date | May 1, 2007 |
| Completion | Sep 1, 2009 |
| First posted | May 4, 2007 |
| Last update posted | Apr 22, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: